The relationship between TNF-α, IL-1, IL-12, IL-17, IL-23, IL-36 expression and treatment response in psoriasis histopathologically and immunohistochemically
- 2 July 2024
- journal article
- research article
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 43 (3) , 182-189
Abstract
There is no marker that can predict whether there is resistance to treatment in patients with psoriasis. In this study, we investigated the relationship between the staining rates of TNF-α, IL-1, IL-12, IL-17, IL-23, and IL-36 markers immunohistochemically from cutaneous biopsy and the treatment success. The patients who were followed up in the dermatology clinic with the diagnosis of plaque-type psoriasis vulgaris and received biological treatment and previously had cutaneous biopsy were included in the study. The cutaneous biopsies of the cases that met the conditions were re-sectioned and subjected to immunohistochemical examination for TNF-α, IL-1, IL-12, IL-17, IL-23, and IL-36. Comparing the staining scores with psoriasis area severity index (PASI); A statistically significant positive correlation was found between PASI and TNF-α staining score(p = 0.034). A statistically significant positive correlation was found between PASI and IL-17 staining score(p = 0.004).When the staining scores and PASI response rates of psoriasis treatment were evaluated in terms of correlation; there was a positive correlation between TNF-α, IL-17, and IL-23 immunohistochemical staining rates and PASI response rates. In line with the data obtained from our study, we think that making immunohistochemical scoring before the biological treatment decision in psoriasis patients will be beneficial in treatment selection. In this respect, our study may open a new era in the selection of biological treatments for psoriasis.Keywords
This publication has 20 references indexed in Scilit:
- Cutaneous immunohistochemical expression of interleukin-23 receptor (IL-23R) in psoriasis and psoriatic arthritis patients: Relation to musculoskeletal ultrasound findingsThe Egyptian Rheumatologist, 2020
- Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamicsJournal of Dermatological Treatment, 2020
- The effect of smoking on the psoriasis: Is it related to nail involvement?Dermatologic Therapy, 2020
- Psoriasis and Atopic DermatitisDermatology and Therapy, 2017
- Increased expression of interleukin‐17 pathway genes in nonlesional skin of moderate‐to‐severe psoriasis vulgarisBritish Journal of Dermatology, 2015
- ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTUREnetworkBritish Journal of Dermatology, 2014
- Cytokine-Based Therapy in PsoriasisClinical Reviews in Allergy & Immunology, 2012
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Affections inflammatoires à médiation immunitaire et psoriasisAnnales de Dermatologie et de Vénéréologie, 2008
- Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis VulgarisJournal of Experimental Medicine, 2004